Seyed Rouhollah Miri

Seyed Rouhollah Miri

Auto-generated profile, based on publicly available information

Seyed Rouhollah Miri

Department of Surgery, Subdivision of Surgical Oncology Cancer Institute, Tehran University of Medical Sciences Tehran Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HDHassan Dana
Hassan Dana
GGhanbar Mahmoodi Chalbatani
Ghanbar Mahmoodi Chalbatani
EGElahe Gharagouzloo
Elahe Gharagouzloo
SMSeyed Rouhollah Miri
Seyed Rouhollah Miri
FMFereydon Memari
Fereydon Memari
VMVahid Marmari
Vahid Marmari
Introduction: Colorectal cancer (CRC) is a type of cancer in humans that leads to high mortality and morbidity. CD166 and CD326 are immunoglobulins that are associated with cell migration. These molecules are included in tumorigenesis of CRC and serve a great marker of CRC stem cells. In the present study, we devised a novel chimeric protein including the V 1-domain of the CD166 and two epitopes of CD326 to use in diagnostic or therapeutic applications. Methods: In silico techniques were launched to characterize the properties and structure of the protein. We have predicted physicochemical properties, structures, stability, MHC class I binding properties and ligand-receptor interaction of this chimeric protein by means of computational bioinformatics tools and servers. The sequence of chimeric gene was optimized for expression in prokaryotic host using online tools and cloned into pET-28a plasmid. The recombinant pET28a was transformed into the E. coli BL21DE3. Expression of recombinant protein was examined by SDS-PAGE and Western blotting. Results: The designed chimeric protein retained high stability and the same immunogenicity as of the original proteins. Bioinformatics data indicated that the epitopes of the synthetic chimeric protein might induce B-cell- and T-cell-mediated immune responses. Furthermore, a gene was synthesized using the codon bias of a prokaryotic expression system. This synthetic gene expressed a bacterial expression system. The recombinant protein with molecular weights of 27kDa was expressed and confirmed by anti-his Western blot analysis. Conclusion: The designed recombinant protein may be useful as a CRC diagnostic tool and for developing a protective vaccine against CRC.

27 May 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
MBMohammad Barary
Mohammad Barary
ABArefeh Babazadeh
Arefeh Babazadeh
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour

30 June 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
ABArefeh Babazadeh
Arefeh Babazadeh
MMMohamad Ali Taghizadeh Moghadam
Mohamad Ali Taghizadeh Moghadam
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS‐CoV‐2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized patients with venous thromboembolism, particularly those admitted to intensive care units. Moreover, various forms of arterial and venous thrombosis, or micro‐ or macro‐vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in patients with COVID‐19 accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life‐threatening condition. In the current paper, we present a thorough review of the pathophysiology of COVID‐19‐induced hypercoagulable state and the use of anticoagulants to treat SARS‐CoV‐2 infections in different patient groups, as well as their pros and cons.

10 March 2022 in Nanomedicine
Verified
Journal Article
Closed access
ASAzar Shams
Azar Shams
RSRonak Shabani
Ronak Shabani
HAHamidreza Asgari
Hamidreza Asgari
MKMahdi Karimi
Mahdi Karimi
MNMohammad Najafi
Mohammad Najafi
MKMorteza Koruji
Morteza Koruji
Aim: MiRNA's-143 and -206 are powerful apoptotic regulators in cancer cells. This study aimed to use miRNA-143- and 206-loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles conjugated with fol...

26 May 2026 in BMC Cancer
Verified
Journal Article
Open access
SESajjad Etesamnia
Sajjad Etesamnia
MNMahdiyar Nasiraie-Moghadam
Mahdiyar Nasiraie-Moghadam
PMPariya Mostafazadeh
Pariya Mostafazadeh
MJMohammad-Reza Jowshan
Mohammad-Reza Jowshan
KRKamran Roudini
Kamran Roudini
SESoraiya Ebrahimpour-Koujan
Soraiya Ebrahimpour-Koujan

11 June 2025 in Cancer Reports
Verified
Journal Article
Open access
AJAmirmohsen Jalaeefar
Amirmohsen Jalaeefar
HMHabibollah Mahmoodzadeh
Habibollah Mahmoodzadeh
MSMohammad Shirkhoda
Mohammad Shirkhoda
RORamesh Omranipour
Ramesh Omranipour
SMSeyed Rouhollah Miri
Seyed Rouhollah Miri
ASAmirsina Sharifi
Amirsina Sharifi
Background: The current standard surgical procedure for gastric cancer (GC) is gastrectomy and D2 lymphadenectomy, which includes harvesting No. 12a lymph node (LN) station. Aim: The purpose of this study was to identify the clinicopathologic factors associated with No. 12a lymph node metastasis. Methods and Results: Eighty‐nine patients with GC undergoing gastrectomy and D2 lymphadenectomy were included in this single‐arm prospective cohort study. Logistic regression analyses were used to clarify the correlation between No. 12a involvement and clinicopathologic characteristics. Eighty‐nine patients (66% males) with a mean age of 58.86 ± 13.06 years were included. The upper third of the stomach was the most common tumor site (43.8%). neoadjuvant chemotherapy (NAC) was administered to 77 patients (86.5%). Total gastrectomy was the most common surgical procedure (67.4%), and 49.4% of tumors were poorly differentiated. Ten patients (11.24%) had 12a LN metastasis. Patients with 12a LN involvement exhibited greater number of harvested LNs in other stations (28.5[27–39.25] vs. 25[21–30], p = 0.024) and a higher presence of LN involvement in other stations (22[11–32] vs. 0[0–4], p = < 0.001). Univariate logistic regression analysis showed that the number of harvested other nodes (OR: 1.11[1.02–1.21]), number of involved other nodes (1.23[1.11–1.37]), omental involvement (OR: 10.86[1.84–64.24.57]), lymphovascular invasion (6.90[1.37–34.70]), and perineuronal invasion (OR: 6.16[1.23–31.11]) were significantly associated with No. 12a station metastasis. However, in multivariate logistic regression, only the number of involved other nodes showed a significant association with No. 12a station metastasis (OR: 1.30[1.09–1.55]). There was no difference between patients who received NAC and who did not in terms of No. 12a involvement ( p value = 0.61). Conclusion: Among clinicopathologic risk factors, involvement of other lymph node stations was significantly associated with No. 12a lymph node metastasis. Therefore, No. 12a lymph node dissection should be considered in patients with advanced gastric cancer.